LRMR
Larimar Therapeutics, Inc.
$2.35
+3.52%
2026-10-23
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Key Fundamentals
Forward P/E
-2.90
EPS (TTM)
$-2.01
ROE
-139.6%
Profit Margin
0.0%
Debt/Equity
3.89
Price/Book
2.52
Beta
0.75
Market Cap
$319.4M
Avg Volume (10D)
1.7M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$4.46
60D Low
$1.92
Avg Volume
1.3M
Latest Close
$2.35
Get breakout alerts for LRMR
Sign up for Breakout Scanner to receive daily notifications when LRMR triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Larimar Therapeutics, Inc. (LRMR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors LRMR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. LRMR operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.